GenomeNet

Database: UniProt
Entry: P01817
LinkDB: P01817
Original site: P01817 
ID   HV205_HUMAN             Reviewed;         119 AA.
AC   P01817; A0A0A0MS10; P01818;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   07-SEP-2016, sequence version 2.
DT   24-JAN-2024, entry version 131.
DE   RecName: Full=Immunoglobulin heavy variable 2-5 {ECO:0000303|PubMed:11340299, ECO:0000303|Ref.5};
DE   AltName: Full=Ig heavy chain V-II region HE {ECO:0000305|PubMed:5264153};
DE   AltName: Full=Ig heavy chain V-II region MCE {ECO:0000305|PubMed:6780622};
DE   Flags: Precursor;
GN   Name=IGHV2-5 {ECO:0000303|PubMed:11340299, ECO:0000303|Ref.5};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (IMGT ALLELE IGHV2-5*02).
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [2]
RP   PROTEIN SEQUENCE OF 20-119, AND PYROGLUTAMATE FORMATION AT GLN-20.
RX   PubMed=5264153; DOI=10.1073/pnas.64.3.997;
RA   Cunningham B.A., Pflumm M.N., Rutishauser U., Edelman G.M.;
RT   "Subgroups of amino acid sequences in the variable regions of
RT   immunoglobulin heavy chains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 64:997-1003(1969).
RN   [3]
RP   PROTEIN SEQUENCE OF 20-119, AND PYROGLUTAMATE FORMATION AT GLN-20.
RX   PubMed=6780622;
RA   Gerber-Jenson B., Kazin A., Kehoe J.M., Scheffel C., Erickson B.W.,
RA   Litman G.W.;
RT   "Molecular basis for the temperature-dependent insolubility of
RT   cryoglobulins. X. The amino acid sequence of the heavy chain variable
RT   region of McE.";
RL   J. Immunol. 126:1212-1216(1981).
RN   [4]
RP   NOMENCLATURE.
RX   PubMed=11340299; DOI=10.1159/000049189;
RA   Lefranc M.P.;
RT   "Nomenclature of the human immunoglobulin heavy (IGH) genes.";
RL   Exp. Clin. Immunogenet. 18:100-116(2001).
RN   [5]
RP   NOMENCLATURE.
RA   Lefranc M.P., Lefranc G.;
RT   "The Immunoglobulin FactsBook.";
RL   (In) Lefranc M.P., Lefranc G. (eds.);
RL   The Immunoglobulin FactsBook., pp.1-458, Academic Press, London. (2001).
RN   [6]
RP   REVIEW ON SOMATIC HYPERMUTATION.
RX   PubMed=17576170; DOI=10.1146/annurev.genet.41.110306.130340;
RA   Teng G., Papavasiliou F.N.;
RT   "Immunoglobulin somatic hypermutation.";
RL   Annu. Rev. Genet. 41:107-120(2007).
RN   [7]
RP   REVIEW ON IMMUNOGLOBULINS.
RX   PubMed=20176268; DOI=10.1016/j.jaci.2009.09.046;
RA   Schroeder H.W. Jr., Cavacini L.;
RT   "Structure and function of immunoglobulins.";
RL   J. Allergy Clin. Immunol. 125:S41-S52(2010).
RN   [8]
RP   REVIEW ON FUNCTION.
RX   PubMed=22158414; DOI=10.1038/nri3128;
RA   McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L.;
RT   "Molecular programming of B cell memory.";
RL   Nat. Rev. Immunol. 12:24-34(2012).
RN   [9]
RP   NOMENCLATURE.
RX   PubMed=24600447; DOI=10.3389/fimmu.2014.00022;
RA   Lefranc M.P.;
RT   "Immunoglobulin and T Cell Receptor Genes: IMGT((R)) and the Birth and Rise
RT   of Immunoinformatics.";
RL   Front. Immunol. 5:22-22(2014).
CC   -!- FUNCTION: V region of the variable domain of immunoglobulin heavy
CC       chains that participates in the antigen recognition (PubMed:24600447).
CC       Immunoglobulins, also known as antibodies, are membrane-bound or
CC       secreted glycoproteins produced by B lymphocytes. In the recognition
CC       phase of humoral immunity, the membrane-bound immunoglobulins serve as
CC       receptors which, upon binding of a specific antigen, trigger the clonal
CC       expansion and differentiation of B lymphocytes into immunoglobulins-
CC       secreting plasma cells. Secreted immunoglobulins mediate the effector
CC       phase of humoral immunity, which results in the elimination of bound
CC       antigens (PubMed:22158414, PubMed:20176268). The antigen binding site
CC       is formed by the variable domain of one heavy chain, together with that
CC       of its associated light chain. Thus, each immunoglobulin has two
CC       antigen binding sites with remarkable affinity for a particular
CC       antigen. The variable domains are assembled by a process called V-(D)-J
CC       rearrangement and can then be subjected to somatic hypermutations
CC       which, after exposure to antigen and selection, allow affinity
CC       maturation for a particular antigen (PubMed:20176268, PubMed:17576170).
CC       {ECO:0000303|PubMed:17576170, ECO:0000303|PubMed:20176268,
CC       ECO:0000303|PubMed:22158414, ECO:0000303|PubMed:24600447}.
CC   -!- SUBUNIT: Immunoglobulins are composed of two identical heavy chains and
CC       two identical light chains; disulfide-linked.
CC       {ECO:0000303|PubMed:20176268}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000303|PubMed:20176268,
CC       ECO:0000303|PubMed:22158414}. Cell membrane
CC       {ECO:0000303|PubMed:20176268, ECO:0000303|PubMed:22158414}.
CC   -!- POLYMORPHISM: There are several alleles. The sequence shown is that of
CC       IMGT allele IGHV2-5*02. {ECO:0000305}.
CC   -!- CAUTION: For examples of full-length immunoglobulin heavy chains (of
CC       different isotypes) see AC P0DOX2, AC P0DOX3, AC P0DOX4, AC P0DOX5 and
CC       AC P0DOX6. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC244226; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A02092; MHHUMC.
DR   PIR; A02093; G1HUHE.
DR   AlphaFoldDB; P01817; -.
DR   EMDB; EMD-23507; -.
DR   EMDB; EMD-28558; -.
DR   EMDB; EMD-28559; -.
DR   EMDB; EMD-32442; -.
DR   EMDB; EMD-32448; -.
DR   EMDB; EMD-32786; -.
DR   EMDB; EMD-32787; -.
DR   EMDB; EMD-34130; -.
DR   EMDB; EMD-34131; -.
DR   EMDB; EMD-34135; -.
DR   SMR; P01817; -.
DR   IMGT_GENE-DB; IGHV2-5; -.
DR   BioMuta; IGHV2-5; -.
DR   DMDM; 123825; -.
DR   MassIVE; P01817; -.
DR   PeptideAtlas; P01817; -.
DR   Ensembl; ENST00000390597.3; ENSP00000375006.2; ENSG00000211937.3.
DR   Ensembl; ENST00000560724.3; ENSP00000473889.3; ENSG00000277318.2.
DR   UCSC; uc059gfq.1; human.
DR   AGR; HGNC:5576; -.
DR   GeneCards; IGHV2-5; -.
DR   HGNC; HGNC:5576; IGHV2-5.
DR   HPA; ENSG00000211937; Tissue enhanced (intestine, lymphoid tissue, stomach).
DR   neXtProt; NX_P01817; -.
DR   OpenTargets; ENSG00000211937; -.
DR   VEuPathDB; HostDB:ENSG00000211937; -.
DR   GeneTree; ENSGT01030000234536; -.
DR   InParanoid; P01817; -.
DR   OMA; CVRRPQR; -.
DR   PhylomeDB; P01817; -.
DR   PathwayCommons; P01817; -.
DR   Reactome; R-HSA-166663; Initial triggering of complement.
DR   Reactome; R-HSA-173623; Classical antibody-mediated complement activation.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-2168880; Scavenging of heme from plasma.
DR   Reactome; R-HSA-2454202; Fc epsilon receptor (FCERI) signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-5690714; CD22 mediated BCR regulation.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   ChiTaRS; IGHV2-5; human.
DR   Pharos; P01817; Tdark.
DR   PRO; PR:P01817; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P01817; Protein.
DR   Bgee; ENSG00000211937; Expressed in rectum and 86 other cell types or tissues.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0019814; C:immunoglobulin complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0003823; F:antigen binding; IBA:GO_Central.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013106; Ig_V-set.
DR   PANTHER; PTHR23266; IMMUNOGLOBULIN HEAVY CHAIN; 1.
DR   PANTHER; PTHR23266:SF259; IMMUNOGLOBULIN HEAVY VARIABLE 2-5; 1.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00406; IGv; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Immunity; Immunoglobulin; Immunoglobulin domain; Membrane;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:5264153,
FT                   ECO:0000269|PubMed:6780622"
FT   CHAIN           20..119
FT                   /note="Immunoglobulin heavy variable 2-5"
FT                   /evidence="ECO:0000269|PubMed:5264153,
FT                   ECO:0000269|PubMed:6780622"
FT                   /id="PRO_0000059910"
FT   DOMAIN          20..>119
FT                   /note="Ig-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   MOD_RES         20
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:5264153,
FT                   ECO:0000269|PubMed:6780622"
FT   DISULFID        41..116
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   CONFLICT        21..26
FT                   /note="ITLKES -> VTLKEN (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        35
FT                   /note="Q -> E (in Ref. 3; AA sequence and 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        43..54
FT                   /note="FSGFSLSTSGVG -> LSGLSLTTDGVA (in Ref. 2; AA
FT                   sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        61..64
FT                   /note="PPGK -> GPGR (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        61
FT                   /note="P -> R (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71..78
FT                   /note="LIYWDDDK -> FINWDDDN (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71..72
FT                   /note="LI -> WLL (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        80
FT                   /note="Y -> F (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        85
FT                   /note="K -> R (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        90..92
FT                   /note="ITK -> VTR (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        90
FT                   /note="I -> G (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="K -> R (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103
FT                   /note="M -> I (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        117
FT                   /note="A -> V (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   NON_TER         119
SQ   SEQUENCE   119 AA;  13231 MW;  7403E23CE450BA92 CRC64;
     MDTLCSTLLL LTIPSWVLSQ ITLKESGPTL VKPTQTLTLT CTFSGFSLST SGVGVGWIRQ
     PPGKALEWLA LIYWDDDKRY SPSLKSRLTI TKDTSKNQVV LTMTNMDPVD TATYYCAHR
//
DBGET integrated database retrieval system